2018
DOI: 10.1093/bioinformatics/bty264
|View full text |Cite
|
Sign up to set email alerts
|

AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing

Abstract: MotivationUnique molecular identifiers (UMIs) are added to DNA fragments before PCR amplification to discriminate between alleles arising from the same genomic locus and sequencing reads produced by PCR amplification. While computational methods have been developed to take into account UMI information in genome-wide and single-cell sequencing studies, they are not designed for modern amplicon-based sequencing experiments, especially in cases of high allelic diversity. Importantly, no guidelines are provided fo… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
47
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(49 citation statements)
references
References 24 publications
2
47
0
Order By: Relevance
“…Although approximately 20% lowered ratios were observed ( Figure 4G), even approximately 0.1% contamination could be reproducibly detected, and these detected values appeared to have good linearity (r Z 0.999). These results suggest that, without the use of a unified molecular identifier, 34 it would be technically difficult to remove PCR bias from quantitative evaluation in this amplicon sequencing case. Nevertheless, these data may support the usefulness of this method for tracking the source of a sample and evaluating cross contamination via an experimental workflow for GPS.…”
Section: Pipeline To Identify the Sample Source And Evaluate Cross-comentioning
confidence: 94%
“…Although approximately 20% lowered ratios were observed ( Figure 4G), even approximately 0.1% contamination could be reproducibly detected, and these detected values appeared to have good linearity (r Z 0.999). These results suggest that, without the use of a unified molecular identifier, 34 it would be technically difficult to remove PCR bias from quantitative evaluation in this amplicon sequencing case. Nevertheless, these data may support the usefulness of this method for tracking the source of a sample and evaluating cross contamination via an experimental workflow for GPS.…”
Section: Pipeline To Identify the Sample Source And Evaluate Cross-comentioning
confidence: 94%
“…UMI-based PCR techniques reduce sequencing error by generating consensus alleles from reads with identical UMIs and mitigate PCR bias by reducing read groups with the same UMI to a single deduplicated read 27 . This protocol incorporates a series of annealing/extension steps to tag single genomic DNA template molecules with the UMI barcode.…”
Section: Standard Pcr and Umi-based Pcr Produce Similar Gestalt Variamentioning
confidence: 99%
“…The published bioinformatic analyses do not provide a means to identify these uninformative variants or a systematic approach to exclude samples with a low fraction of informative barcodes. Unique molecular identifiers (UMIs) have been used for sequencing error, PCR error, and PCR bias correction 27 , however the UMI PCR protocol more than doubles the sample preparation time and reagent cost, and the extent to which UMIs improve accuracy over standard PCR has not been demonstrated in this setting.…”
mentioning
confidence: 99%
“…There are three reputable databases [1,39,46] that compile accurate information on BRCA1/2 variants classification based on multiple evidences from different sources combined into a Bayesian model to generate a posterior probability and validated by an expert panel [28]: ClinVar, BRCA Exchange, and BRCA Share. In ClinVar, the classification is reliable only if the "review status" contains three stars, meaning that it has been validated by the ENIGMA [25] expert panel, while BRCA Exchange [1] provides the same classification as ClinVar in a more userfriendly environment and more detailed information [14], including a mobile app that provides reclassification updates on variants of interest. On the other hand, BRCA Share™ [7] compiles data from 16 academic laboratories performing BRCA1/2 testing in France.…”
Section: Post-analytical Phase Ii: Variant Interpretationmentioning
confidence: 99%